tg02
Small moleculeexperimental
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01204164)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Astrocytoma · Phase 1/Phase 2
- Blast Crisis · Phase 1
- Brain Neoplasms · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 1
- Glioblastoma · Phase 1/Phase 2
- Glioma · Phase 1
- Gliosarcoma · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Lymphoid · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1/Phase 2
- Rectal Neoplasms · Phase 1
Mechanism of action
- Cyclin-dependent kinase 1INHIBITOR
CDK1 inhibitor
FLT3 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
- Cyclin-dependent kinase 9INHIBITOR
CDK9 inhibitor
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
- Cyclin-dependent kinase 7INHIBITOR
CDK7 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1- Mol. weight
- 372.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1944698 ↗
Also known as
- 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene
- sb1317
- sb-1317
- sb-1317
- tg02
- tg02
- tg02
- tg02
- tg-02
- tg-02
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05588141 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2022 | National Cancer Institute (NCI) |
| NCT03904628 | Phase 1 | Apr 1, 2019 | Lee's Pharmaceutical |
| NCT03738111 | Phase 1 | Dec 31, 2018 | Lee's Pharmaceutical |
| NCT03224104 | Phase 1 | Jun 30, 2018 | Adastra Pharmaceuticals, European Organisation for Research and Treatment of Cancer, University of Lille |
| NCT02942264 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2016 | National Cancer Institute (NCI) |
| NCT02933944 | Phase 1 | Sep 1, 2016 | Targovax ASA |
| NCT01699152 | Phase 1 | Sep 1, 2012 | Adastra Pharmaceuticals |
| NCT01204164 | Phase 1 | Aug 1, 2010 | Adastra Pharmaceuticals |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adastra Pharmaceuticals | For profit | 3 | 2 | 1 | 2010 |
| Lee's Pharmaceutical | For profit | 2 | 2 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 2016 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Targovax ASA | For profit | 1 | 1 | 1 | 2016 |
| University of Lille | Academic/Hospital | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1